Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: SST.2008.4.1.1. | Award Amount: 5.58M | Year: 2009
There is an urgent need to have a confident toxicity measurement methodology that contributes to the existing level of surface transport fire safety, which is the most difficult issue to assess in case of fire. The lack of confidence in the robustness of the existing product toxicity classification forbids its acceptance as a standard which prevent the European industry from common safety rules and consequently competitiveness. Moreover, it is also important to have a holistic approach of fire safety design of vehicle being able to provide more flexible and economic solutions than the current approach. TRANSFEU undertakes to deliver both a reliable toxicity measurement methodology and a holistic fire safety approach for all kind of surface transport (trains, vessels, etc.). It will be based on a harmonized Fire Safety Engineering methodology which will link passive fire security with active fire security mode. This all embracing system is the key to attain optimum design solutions to respect fire safety objectives as an alternative to the prescriptive approach. It will help in the development of innovative solutions (design and products used for the building of the surface transport) which will better respect the environment. In order to reach these objectives new toxicity measurement methodology and related classification of materials, new numerical fire simulation tools, fire test methodology and a decision tool to optimize or explore new design in accordance to the fire safety requirements will be developed. A great effort of dissemination of TRANSFEU results with a significant contribution to European standardization process will also be undertaken. The participation of railway industrials, operators and fire science researchers, professional organisations for railway (UNIFE) and vessels (IMO) and finally standardisation organisations (CEN) demonstrates the great interest of TRANSFEU for the harmonisation of fire safety in all surface transports.
Wetzstein H.-G.,Bayer Animal Health GmbH |
Schneider J.,Bayer CropScience |
Karl W.,Currenta GmbH
AMB Express | Year: 2012
Liquid cultures of the basidiomycetous fungus Gloeophyllum striatum were employed to study the biodegradation of pradofloxacin, a new veterinary fluoroquinolone antibiotic carrying a CN group at position C-8. After 16 days of incubation, metabolites were purified by micro-preparative high-performance liquid chromatography. Four metabolites could be identified by co-chromatography with chemically synthesized standards. The chemical structures of three compounds were resolved by 1H-nuclear magnetic resonance spectroscopy plus infrared spectroscopy in one case. All metabolites were confirmed by high resolution mass spectrometry-derived molecular formulae. They comprised compounds in which the carboxyl group or the fluorine atom had been exchanged for a hydroxyl group. Furthermore, replacement of the CN group and the intact amine moiety by a hydroxyl group as well as degradation of the amine substituent were observed. The chemical structure of a catechol-type fluoroquinolone metabolite (F-5) could be fully defined for the first time. The latter initiated a hypothetical degradation sequence providing a unique metabolite, F-13, which consisted of the cyclopropyl-substituted pyridone ring still carrying C-7 and C-8 of pradofloxacin, now linked by a double bond and substituted by a hydroxyl and the CN group, respectively. Most likely, all reactions were hydroxyl radical-driven. Metabolite F-13 proves fungal cleavage of the aromatic fluoroquinolone core for the first time. Hence, two decades after the emergence of the notion of the non-biodegradability of fluoroquinolones, fungal degradation of all key structural elements has been proven. © 2012 Springer-Verlag Berlin Heidelberg.
News Article | February 23, 2017
Après l’ouverture de nouveaux locaux à Boston en 2016, d’autres bureaux au Royaume-Uni, en France, en Suisse et en Australie verront le jour cette année. La plateforme de transformation digitale Signavio offre aux organisations à travers le monde, la solution dont elles ont besoin pour gérer le changement. Selon Christoph Garbers, Currenta GmbH & Co. OHG, client Signavio : „Signavio nous aide à trouver un nouveau langage collaboratif et nous donne l’assurance nécessaire de mettre en oeuvre la bonne solution.“ Le fournisseur allemand de solutions logicielles, dont le siège social est basé à Berlin et qui est également implanté à Sunnyvale, Californie, à Boston, Massachusetts et à Singapour, offre des solutions en ligne pour modéliser, analyser, et optimiser les processus métier et décisions opérationnelles. Grâce à ses logiciels en SaaS, Signavio allie une solution professionnelle BPM et BDM aux avantages collaboratifs d’un service sur le cloud.
News Article | February 23, 2017
BERLIN--(BUSINESS WIRE)--Over 1,000 customers worldwide now understand and plan their business processes better thanks to Signavio. Corporations need to know how to implement business processes successfully and react consistently to new challenges, which is why Signavio tripled its customer base over the last three years. Now, the German cloud-based software provider Signavio, headquartered in Berlin, is continuing its internationalization strategy. This year, Signavio is cementing its international presence by opening four additional locations. “ The demand for our products has quickly increased in many countries. Creating close customer relationships is very important to us, so having a stronger presence in these regions is of top priority. These new locations will allow us to support our customers even better than we already do,” says Dr. Gero Decker, CEO of Signavio. After opening the new US office in Boston in 2016, additional offices in Great Britain, France, Switzerland, and Australia will be established in 2017. The Signavio Business Transformation Platform offers organizations across the world the ability to successfully implement change. Signavio customer Christoph Garbers of Currenta GmbH & Co. OHG says: “ Signavio helps us to find a new language collaboratively, and gives us the assurance we need that we are implementing the right solution.” The Signavio team is also growing fast. Signavio welcomed new COO, Mark Holenstein, in January. Holenstein is in charge of the company’s international growth strategy. Before his appointment with Signavio, he was responsible for the Europe, Middle East, and Africa regions at Hybris AG. After the acquisition of Hybris by SAP SE, he was Executive Vice President for the CRM and omni-commerce business at SAP SE. “ The expansion is an important step towards furthering the international presence of Signavio. I am looking forward to meeting this challenge together with the Signavio team,” says Mark Holenstein, Signavio COO. The Signavio Business Transformation Platform is available as a free test version for 30 days. Register here: signavio.com/try. Signavio offers web-based solutions for the modeling, analysis and optimization of business processes and decisions. Through its SaaS-Software, the company combines the advantages of a professional BPM and BDM solution with those of cloud collaboration.
News Article | February 23, 2017
BERLIN--(BUSINESS WIRE)--Mehr als 1.000 Kunden weltweit hat Signavio bereits geholfen, Geschäftsprozesse zu verstehen und zu planen. Unternehmen können so Veränderungsvorhaben erfolgreich umsetzen und immer wieder auf neue Herausforderungen reagieren. In den letzten drei Jahren konnte das Unternehmen so seine Kundenbasis verdreifachen. Nach der Eröffnung der neuen US-Zentrale in Boston im Jahr 2016 entstehen nun weitere Niederlassungen in Großbritannien, Frankreich, der Schweiz und Australien. Mit der Signavio Business Transformation Platform bietet das Unternehmen Organisationen weltweit die nötige Basis, um erfolgreich Veränderungen umzusetzen. So sagt beispielsweise Signavio-Kunde Christoph Garbers von der Currenta GmbH & Co. OHG: „ Signavio hilft uns, eine gemeinsame Sprache zu finden und gibt uns die Sicherheit, das Richtige umzusetzen.“
Kreiss W.,Currenta GmbH |
Frode R.,Bayer AG |
Mohrle V.,Bayer AG
Analytical and Bioanalytical Chemistry | Year: 2010
By employing a novel technique for the direct coupling of a bacterial bioassay with chromatography, we discovered a gyrA promotor active compound in myxobacterial extracts and elucidated the structure directly without any isolation step. As a result, we identified inthomycin A as the bioactive substance. Our method is based on a whole-cell bioluminescent reporter gene assay coupled with thin-layer chromatography for primary hit detection and with liquid chromatography (LC)/mass spectrometry or LC/NMR for dereplication and structure elucidation. Previously, inthomycin A has been isolated from Streptomycetes and was associated with the inhibition of cellulose biosynthesis and herbicidal activity. Thus, our findings support the basic principle that completely different microbial phyla are able to synthesize the same natural product. Moreover, our results indicate that inthomycin A affects bacterial DNA supercoiling, which reveals an unexpected bioactivity for this compound. These results can possibly promote further investigation of the biosynthesis as well as the biological activity of inthomycins and related natural products. © 2010 Springer-Verlag.
Eckert E.,Friedrich - Alexander - University, Erlangen - Nuremberg |
Leng G.,Currenta GmbH |
Gries W.,Currenta GmbH |
Goen T.,Friedrich - Alexander - University, Erlangen - Nuremberg
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences | Year: 2012
We developed and validated an analytical method for the simultaneous determination of several chlorine and non-chlorine containing mercapturic acids in urine as specific metabolites of the hazardous chemicals 2-chloroprene and epichlorohydrin. The method involves an online column switching arrangement for online solid phase extraction of the analytes with subsequent analytical separation and detection using LC-MS/MS. The developed method enables for the first time the determination of Cl-MA-I (4-chloro-3-oxobutyl mercapturic acid), Cl-MA-II (4-chloro-3-hydroxybutyl mercapturic acid), Cl-MA-III (3-chloro-2-hydroxy-3-butenyl mercapturic acid) and HOBMA (4-hydroxy-3-oxobutyl mercapturic acid) as potential biomarkers of 2-chloroprene in urine. Additionally, CHPMA (3-chloro-2-hydroxypropyl mercapturic acid) as a specific metabolite of epichlorohydrin in urine and DHBMA (3,4-dihydroxybutyl mercapturic acid) can be determined. The analytical method proved to be both sensitive and reliable with detection limits ranging from 1.4 μg/L (for Cl-MA-III) to 4.2 μg/L (for HOBMA). Intra- and interday imprecision was determined to range from 4.7 to 11.8%. Due to the good accuracy and precision and the low limits of detection the developed method is well suited for application in biomonitoring studies in order to determine occupational exposure to 2-chloroprene and epichlorohydrin. © 2012 Elsevier B.V.
Leng G.,Currenta GmbH
Zentralblatt fur Arbeitsmedizin, Arbeitsschutz und Ergonomie | Year: 2016
Introduction: Biomonitoring results from employees working in the production of isocyanates (collective 1) as well as from parquet recliners applying isocyanates (collective 2) are presented. The following isocyanates were investigated: methylene diphenyl diisocyanate (4,4-MDI), toluene diisocyanate (2,4 and 2,6-TDI) and hexamethylene diisocyanate (HDI). For the biomonitoring the corresponding amine from the isocyanate was determined by gas chromatography-mass spectrometry (GC/MS), i. e. MDA, 2,4-TDA, 2,6-TDA and HDA. Moreover, in the parquet recliner study an ambient monitoring was carried out. Collective 1: The highest HDI values were measured in employees working in the control room and administration. Workers with direct access in the production did not have any body burden, i. e. personal protection equipment was adequate. The results showed that the reason for the body burden was insufficient hygiene in the working environment with the consequence that the contamination was spread into the clean area. Collective 2: The application of isocyanates in parquet recliners did not lead to a mentionable body burden; therefore, the substitution of products containing high levels of solvents by adhesives and sealing compounds containing isocyanates can be recommended. © 2016, Springer-Verlag Berlin Heidelberg.
Gries W.,Currenta GmbH |
Leng G.,Currenta GmbH
Analytical and Bioanalytical Chemistry | Year: 2013
4,4′-Methylene diphenyl diisocyanate (MDI) is one of the most important isocyanates in the industrial production of polyurethane and other MDI-based synthetics. Because of its high reactivity, it is known as a sensitizing agent, caused by protein adducts. Analysis of MDI is routinely done by determination of the nonspecific 4,4′-methylenedianiline as a marker for MDI exposure in urine and blood. Since several publications have reported specific adducts of MDI and albumin or hemoglobin, more information about their existence in humans is necessary. Specific adducts of MDI and hemoglobin were only reported in rats after high-dose MDI inhalation. The aim of this investigation was to detect the hemoglobin adduct 5-isopropyl-3-[4-(4- aminobenzyl)phenyl]hydantoin (ABP-Val-Hyd) in human blood for the first time. We found values up to 5.2 ng ABP-Val-Hyd/g globin (16 pmol/g) in blood samples of workers exposed to MDI. Because there was no information available about possible amounts of this specific MDI marker, the analytical method focused on optimal sensitivity and selectivity. Using gas chromatography-high-resolution mass spectrometry with negative chemical ionization, we achieved a detection limit of 0.02 ng ABP-Val-Hyd/g globin (0.062 pmol/g). The robustness of the method was confirmed by relative standard deviations between 3.0 and 9.8 %. Combined with a linear detection range up to 10 ng ABP-Val-Hyd/g globin (31 pmol/g), the enhanced precision parameter demonstrates that the method described is optimized for screening studies of the human population. © 2013 Springer-Verlag Berlin Heidelberg.
Currenta GmbH | Date: 2014-12-09
The present invention relates to a method for decoupling the provision of electricity and high-pressure steam of a combined heat and power plant which has the primary purpose of providing process steam, i.e. which is heat-led.